Group items tagged

The Climate and Environmental Sciences Division (CESD), Office of Biological and Environmental Research (BER) of the Office of Science (SC), U.S. Department of Energy (DOE), in collaboration with the Amazonas Research Foundation and the S?o Paulo Research Foundation of Brazil, hereby announces its interest in collaborative grant research applications in support of the upcoming GreenOceanAmazon2014 experiment (GOAmazon2014).

The Mastocytosis Society, Inc. (TMS) and Mastokids (MKO) are pleased to announce that we are accepting proposals for research grants for new or ongoing projects related to Pediatric Mastocytosis or Pediatric Mast Cell Activation Syndrome.

The prize will be awarded on the basis of scientific merit for independent research dealing with synthesis in the broadest context of organic chemistry, including organometallic chemistry, medicinal and biological chemistry, designed molecules, and materials. Candidates must be under 40 years of age as of January 1 of the year in which the prize is awarded.

JDRF, the world's leading non-profit organization with the mission to cure type 1 diabetes (T1D), invites applications from research investigators having interest and expertise to support the discovery and advancement of biomarkers of pancreatic beta cell stress and health correlating with early beta-cell loss.

This program will support projects to develop cognition biomarkers or combinations of biomarkers that help to identify the transitions between normal cognition and cognitive impairment, and between cognitive impairment and dementia.

EPA's Office of Pesticide Programs (OPP), in coordination with the EPA Regional Offices, announces the availability of approximately $506,000 for FY13 to further, through research, development, monitoring, public education, training, demonstrations, or studies, the adoption of Integrated Pest Management (IPM) approaches to reduce pesticide risk in production agriculture settings in the United States. IPM is a sustainable approach to managing pests by combining biological, cultural, physical, and chemical tools in a way that minimizes economic, health, and environmental risks.

This is a onetime seed grant of $25,000 for basic or clinical research directly related to hypophosphatasia.

The Michael J. Fox Foundation for Parkinson's Research (MJFF) seeks to fund pre-clinical studies that investigate the biological function and therapeutic potential of Parkin protein. The ultimate goal is to identify therapeutic agents that alter the course of Parkinson's disease. There will be two separate 'Tracks' that may be pursued for support around Parkin as follows: TRACK A - Biology TRACK B - Therapeutic Development Applicants may submit proposals to both Track A and Track B but it will need to do so by submitting separate applications that provide independent experimental designs for each. Applicants will be asked to justify the approach and to provide details of their study design. Biological Studies How will the proposed studies impact our understanding of Parkin: As an enzyme In cell biology Therapeutic Development Studies Current drug development stage with clear justification Provide  research operation plan, including feasibility, timelines, and all assays to be performed Provide a clear description of the properties of the lead compound(s)/biologic

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and participating Institutes invite grant applications for research on the development of safe, real-time, non-invasive (or minimally invasive), in vivo methods to assess the development and function of the human placenta.

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and participating components invite grant applications for research on the development of safe, real-time, non-invasive (or minimally invasive), in vivo methods to assess the development and function of the human placenta.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to phenotype embryonic lethal knockout (KO) mouse strains being generated through the International Mouse Phenotyping Consortium (IMPC) of which the NIH Knockout Mouse Phenotyping Program (KOMP2) is a member. It is estimated that KO mouse phenotyping efforts will generate 20,000 mouse strains over the next decade of which about 30% will be embryonic or perinatal lethal. A large portion of homozygous lethal mutations are expected to have viable heterozygous phenotypes. The scientific community has the unique opportunity to leverage these mouse strains while they are being created and bred as part of the IMPC adult mouse phenotyping effort.

The USGS is offering a funding opportunity to a CESU partner to develop hydrodynamic models that describe the transport of bacteria in the nearshore Great Lakes, specifically linking them to water chemistry and human health. This CESU project will provide support for two years.

The objectives of the Molecular Signatures program are to identify and characterize critical molecular signatures relevant to Intelligence, Surveillance, and Reconnaissance (ISR) and Human Performance; to develop sensors for the detection of these signatures utilizing molecular, genomic, and nano-bio sensing elements; and to develop and employ data analysis tools for processing, exploitation, and dissemination of detected signatures for informed and efficient decision making.

The PRMRP Investigator-Initiated Research Award (IIRA) is intended to support studies that will make an important contribution toward research and/or patient care for a disease or condition related to at least one of the Congressionally directed FY13 PRMRP Topic Areas. The rationale for a research idea may be derived from a laboratory discovery, population-based studies, a clinician's first-hand knowledge of patients, or anecdotal data. Applications must include relevant data that support the rationale for the proposed study. These data may be unpublished or from the published literature. Research projects may focus on any phase of research from basic laboratory research through translational research, including preclinical studies in animal models and human subjects, as well as correlative studies associated with an existing clinical trial. Research involving human subjects and human anatomical substances is permitted; however, this award may not be used to conduct clinical trials.

The PRMRP Technology/Therapeutic Development Award (TTDA) is a product-driven award intended to provide support for the translation of promising preclinical findings into products for clinical applications, including prevention, detection, diagnosis, patient care, and/or quality of life, in at least one of the Congressionally directed FY13 PRMRP Topic Areas. Products in development should be responsive to the health care needs of military service members,Veterans, and/or beneficiaries. The product(s) to be developed may be pharmacologic agents (drugs or biologics), devices, and/or clinical guidance for standard of care. The Principal Investigator (PI) must provide a transitio

A. Proposals for the development of novel collaborative perception algorithms that will enable heterogeneous teams of UxS (specifically unmanned air and ground systems) to share knowledge and perform joint target search and tracking autonomously. While existing distributed data fusion methods have looked at probabilistic representations for fusing detections at a decision level, work is needed to investigate shared perceptual features that exist across unmanned air and ground systems to enable the performance of collaborative tasks.  B. Development of a new Rigid Body Dynamics Software Library for Mathematical and Physics-Based Modeling and Simulation. The basic research proposed here would involve the development of a new software library for the temporal (time) integration of the governing equations of rigid body dynamics. The temporal integration technique employed in this new library involves the application of the Runge-Kutta method of various orders and possibly other finite-difference-type techniques to a system of equations consisting of kinematic equations (arising from the Lie Group structure of the group of rotation transformations) which define the first and second time derivatives of the rotation transformation in terms of angular velocity and angular acceleration together with the equations of motion (balance of momentum and balance of angular momentum) of a rigid body. C. Robustness of the Use of Botanical DNA Materials as Anti-Counterfeit Markers for Electronic Components - The project will solicit academic laboratory participation for doing testing that demonstrates the 'robustness' of the use of Botanical DNA material as anti-counterfeit markers for electronic components. Request analysis of candidate DNA marker materials utilizing current DNA manipulation technology. This would be done especially in light of results from (1) above.

The Small Business Innovation Research (SBIR) Program stimulates technological innovation in the private sector by strengthening the role of small business concerns in meeting Federal research and development needs, increasing the commercial application of federally supported research results, and fostering and encouraging participation by socially and economically disadvantaged and women-owned small businesses. The SBIR program solicits proposals from the small business sector consistent with NSF's mission. The program is governed by Public Law 112-81 (SBIR/STTR Reauthorization Act of 2011). A main purpose of the legislation is to stimulate technological innovation and increase private sector commercialization. The NSF SBIR program is therefore in a unique position to meet both the goals of NSF and the purpose of the SBIR legislation by transforming scientific discovery into both social and economic benefit, and by emphasizing private sector commercialization. Accordingly, NSF has formulated broad solicitation topics for SBIR that conform to the high-technology investment sector's interests. The topics are: Biological and Chemical Technologies (BC) Education Applications (EA) Electronics, Information and Communication Technologies (EI) Nanotechnology, Advanced Materials, and Manufacturing (NM)

The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. Through this solicitation, the NIAID Division of Allergy, Immunology and Transplantation plans to support the early stage discovery and initial characterization of novel adjuvant candidates. Thus, research solicited under this acquisition will contribute to the pipeline of new adjuvant leads that either (a) exploit the natural capacity of the innate immune system to initiate and sustain effective T and B cell responses and to induce long term immune memory or (b) act directly on lymphocytes to enhance their response to pathogen-derived antigens.